Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-Intensity Allogeneic HCT After Prior Autologous Transplant
NCT01118013Phase 2Terminated
- Sponsor
- Cancer and Leukemia Group B
- Start
- Dec 2010
- Primary completion
- Mar 2012
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of busulfan, fludarabine in chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), multiple myeloma (MM), sponsored by Cancer and Leukemia Group B. Started Dec 2010; status: terminated.
02
Drugs
busulfanfludarabine
03
Conditions
chronic lymphocytic leukemia (CLL)prolymphocytic leukemia (PLL)non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01118013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01118013.